Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term ...

Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna’s share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from ...

A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests ​to dismiss patent lawsuits filed ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its ...

Sanofi (Nasdaq: SNY) deprioritized its mRNA flu shot effort. But it is still vigorously defending its substantial share of the flu vaccine market, with its egg-grown Fluzone products and egg-free ...

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...